Gene Therapy for Parkinson’s Disease - Viral Vector Approaches in Neurobiology and Brain Diseases - page 182

Acknowledgments

The authors are indebted to Christina Isaksson, Ulla Jarl, Anneli
Josephsson, and Michael Sparrenius for their technical expertise.
The work was supported by the Swedish Research Council (Grants
# 2010-4496 and 2007-8626).

References

1. Kirik D et al (2002) Reversal of motor impair-
ments in parkinsonian rats by continuous
intrastriatal delivery of L-dopa using rAAV-
mediated gene transfer. Proc Natl Acad Sci
USA 99:4708-4713
2. Bjorklund T et al (2010) Optimized adeno-
associated viral vector-mediated striatal DOPA
delivery restores sensorimotor function and
prevents dyskinesias in a model of advanced
Parkinson's disease. Brain 133:496-511
3. Carlsson T et al (2005) Reversal of dyskinesias
in an animal model of Parkinson's disease by
continuous L-DOPA delivery using rAAV vec-
tors. Brain 128:559-569
4. Bankiewicz KS et al (2006) Long-term clinical
improvement in MPTP-lesioned primates after
gene therapy with AAV-hAADC. Mol Ther
14:564-570
5. Sanchez-Pernaute R et al (2001) Functional
effect of adeno-associated virus mediated gene
transfer of aromatic L-amino acid decarboxyl-
ase into the striatum of 6-OHDA-lesioned
rats. Mol Ther 4:324-330
6. Muramatsu S et al (2010) A phase I study of
aromatic L-amino acid decarboxylase gene
therapy for Parkinson's disease. Mol Ther
18:1731-1735
7. Christine CW et al (2009) Safety and tolerabil-
ity of putaminal AADC gene therapy for
Parkinson disease. Neurology 73:1662-1669
8. Muramatsu S et al (2002) Behavioral recovery in
a primate model of Parkinson's disease by triple
transduction of striatal cells with adeno-associated
viral vectors expressing dopamine-synthesizing
enzymes. Hum Gene Ther 13:345-354
9. Azzouz M et al (2002) Multicistronic lentiviral
vector-mediated striatal gene transfer of aro-
matic L-amino acid decarboxylase, tyrosine
hydroxylase, and GTP cyclohydrolase I induces
sustained transgene expression, dopamine pro-
duction, and functional improvement in a rat
model of Parkinson's disease. J Neurosci 22:
10302-10312
10. Oxford BioMedica (2011) ProSavin, an
innvative gene-based therapy for Parkinson's
disease
11. Zibetti M et al (2011) Beyond nine years of
continuous subthalamic nucleus deep brain

stimulation in Parkinson's disease. Mov Disord
26:2327-2334
12. Alvarez L et al (2009) Therapeutic effi cacy of
unilateral subthalamotomy in Parkinson's dis-
ease: results in 89 patients followed for up to
36 months. J Neurol Neurosurg Psychiatry
80:979-985
13. Luo J et al (2002) Subthalamic GAD gene
therapy in a Parkinson's disease rat model.
Science 298:425-429
14. Lee B et al (2005) Enhanced expression of
glutamate decarboxylase 65 improves symp-
toms of rat parkinsonian models. Gene Ther
12:1215-1222
15. Emborg ME et al (2007) Subthalamic glu-
tamic acid decarboxylase gene therapy: changes
in motor function and cortical metabolism.
J Cereb Blood Flow Metab 27:501-509
16. Lewitt PA et al (2011) AAV2-GAD gene ther-
apy for advanced Parkinson's disease: a double-
blind, sham-surgery controlled, randomised
trial. Lancet Neurol 10:309-319
17. Kaplitt MG et al (2007) Safety and tolerability
of gene therapy with an adeno-associated virus
(AAV) borne GAD gene for Parkinson's dis-
ease: an open label, phase I trial. Lancet
369:2097-2105
18. Nutt JG et al (2003) Randomized, double-
blind trial of glial cell line-derived neuro-
trophic factor (GDNF) in PD. Neurology
60:69-73
19. Patel NK et al (2005) Intraputamenal infusion
of glial cell line-derived neurotrophic factor in
PD: a two-year outcome study. Ann Neurol
57:298-302
20. Gill SS et al (2003) Direct brain infusion of
glial cell line-derived neurotrophic factor in
Parkinson disease. Nat Med 9:589-595
21. Hovland DN Jr et al (2007) Six-month
continuous intraputamenal infusion toxicity
study of recombinant methionyl human
glial cell line-derived neurotrophic factor
(r-metHuGDNF in rhesus monkeys. Toxicol
Pathol 35:1013-1029
22. Herzog CD et al (2009) Expression, bioactiv-
ity, and safety 1 year after adeno-associated
viral vector type 2-mediated delivery of neur-
turin to the monkey nigrostriatal system